Current Report Filing (8-k)
30 Novembre 2012 - 10:27PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of
1934
Date of Report (Date of earliest event reported)
November 30, 2012 (November 29, 2012)
NEUROGESX,
INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
DELAWARE
|
|
001-33438
|
|
94-3307935
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
999 Baker Street, Suite 200, San Mateo, California 94404
(Address of principal executive offices, including zip code)
650-358-3300
(Registrants telephone number, including area code)
(Former name
or former address, if changed since last report)
Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 2.05. Costs Associated with Exit or Disposal Activities.
On November 29, 2012, the Company committed to reducing its workforce by nine individuals. The restructuring is to
further align the organization and personnel with the Companys current requirements based on the operating model needed to achieve the Companys business strategy focusing on the clinical development program for
its primary product candidate, NGX-1998. The Company communicated the plan to the impacted employees on or about November 29, 2012 with the expectation that the restructuring will be completed by December 31, 2012. The impacted
employees are eligible to receive cash severance contingent on their signing of a general release with the Company. Assuming that all employees are paid severance, the Company expects to record a cash charge for severance and other payroll related
termination costs of approximately $280,000 in the fourth quarter of 2012.
Item 8.01. Other Events
The discussion set forth in Item 2.05 above is hereby incorporated by reference into this Item 8.01, and is deemed to be filed
for purposes of the Securities Exchange Act of 1934, as amended.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
NEUROGESX, INC.
|
|
|
By:
|
|
/s/ Stephen F. Ghiglieri
|
|
|
|
|
|
Stephen F. Ghiglieri
|
|
|
Executive Vice President, Chief Operating Officer & Chief Financial Officer
|
Date: November 30, 2012
3
Fidelity Bancorp (NASDAQ:FSBI)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Fidelity Bancorp (NASDAQ:FSBI)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024
Real-Time news about Fidelity Bancorp, Inc. (MM) (NASDAQ): 0 recent articles
Plus d'articles sur Neurogesx Inc